NewsRoom Articles - Page 48 of 154 - PsychedelicNewsWire (PNW)

WednesdaySep 28, 2022 1:04 pm

Psychedelics Feature During Congressional Ways and Means Committee Meeting

Last week, Rep. Earl Blumenauer discussed the therapeutic potential of psychedelic drugs as alternatives to traditional drugs for mental health disorders during a House Ways and Means Committee meeting. During the meeting, legislators talked about proposals on family and worker access to health support. The congressman stated that while he was encouraged by how legislators were moving forward with integrating various reform areas, including outpatient care, there was still a need to advance the search for therapies that could help to better manage mental health conditions; he proposed that psychedelics be included in the healthcare improvements discussion. His statement was…

TuesdaySep 27, 2022 12:00 pm

Ancillary Firms to Play Bigger Role in Psychedelics Space

For a while now, researchers have been conducting studies on psychedelics, gathering more knowledge on these substances and their benefits. Prior research has demonstrated that psychedelics could help manage anxiety, treatment-resistant depression and post-traumatic stress disorder for individuals who haven’t benefitted from the currently prescribed medications. As the psychedelics space grows, so do investments into the market. Unsurprisingly, the number of nondrug startups involved in the space has increased considerably, moving from 19% in 2020 to 38% in 2021. However, with the market reaching oversaturation and funding for biotech startups drying up, many believe that ancillary tech firms will be…

MondaySep 26, 2022 12:00 pm

An Analysis of Psychedelics in End-of-Life Care

Psychedelics are slated to disrupt psychiatry in a major way. Although there is limited research on the possible benefits of hallucinogenic drugs, recent studies have found that they can have significant mental health benefits. Researchers have discovered that when paired with psychotherapy, psychedelics can deliver profound benefits for people with mental health conditions, including PTSD, anxiety, depression and eating disorders. Specifically these mental health benefits, especially against anxiety and depression, can come in handy for patients in palliative or end-of-life care. Receiving a terminal diagnosis often results in feelings of grief, anxiety and depression. According to researchers from Baylor University…

FridaySep 23, 2022 11:15 am

Researchers Investigate Whether Psilocybin Mushrooms Can Help Combat Obesity

Psilocybin is the primary active compound found in hallucinogenic mushrooms. This compound usually turns into psilocin upon consumption. Recent research has provided evidence showing that psilocybin-assisted therapy may be effective in treating addiction, which has led others to wonder whether the psychedelic could also help individuals to control food cravings. A 2021 study also found that individuals who had ingested a classic psychedelic at least once in their lives had a considerably lower chance of being obese or overweight. These findings prompted a group of investigators to begin conducting research on whether psilocybin could help treat eating disorders and obesity.…

ThursdaySep 22, 2022 12:45 pm

Trial Clinic for Psychedelics to Open in London

After decades of prohibition and criminalization, various jurisdictions around the world have begun to loosen their restrictive psychedelic policies in what has been dubbed the psychedelics renaissance. There has been a significant surge in psychedelic interest among the scientific community, with researchers running several studies to look into the potential benefits and risks of using hallucinogenic drugs medicinally. Research has already shown that psychedelics have plenty of promise as treatments for mental-health conditions such as PTSD, depression and eating disorders, especially when paired with psychotherapy. Researchers in London have been conducting clinical trials to test the potential of psychedelics as…

WednesdaySep 21, 2022 3:58 pm

Native American Church Appeals to Congress to Fund Preservation, Cultivation of Peyote

Last week, leaders of the Native American Church (NAC) asked Congress to allocate funds toward efforts to preserve lands where peyote can be cultivated. Peyote is a psychedelic cacti that is often used in religious ceremonies of the Native American Church. The plant’s primary habitat is located in Texas, near the United States-Mexico border. The federally protected plant is classified as a Schedule I substance but can be cultivated, harvested and used by the church, per an amendment to the American Indian Religious Freedom Act. Despite federal protections, the plant’s supply is limited, which is why members of this particular…

TuesdaySep 20, 2022 12:57 pm

Hamilton Morris Confirmed as Keynote Speaker at Convergence Psychedelic Conference

Convergence, the biggest psychedelic culture and business conference in California, recently announced that Hamilton Morris would be a keynote speaker at the conference. Morris is a well-known advocate in the psychedelics space. In addition to being a scientific researcher, a journalist and a filmmaker, he has a television show known as “Hamilton’s Pharmacopeia.” The show, which runs on Vice TV, allows him to bring life to stories and experiences of psychedelics along with the uses of these substances and their cultural significance and the chemistry behind them. At the moment, Morris is a consultant at Compass Pathway’s Discover Center, which…

TuesdaySep 20, 2022 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical development Cybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybin The high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective therapeutics. The company is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. Late last month, the first two trial participants…

MondaySep 19, 2022 10:58 am

An Overview of San Francisco’s Psychedelics Decriminalization Measure

Last week, the city of San Francisco decriminalized entheogenic substances after its Board of Supervisors unanimously passed a measure that made entheogens the lowest priority for city law enforcement. The measure was sponsored by Supervisors Hillary Ronen and Dean Preston. Its approval is a victory for Decriminalize Nature’s San Francisco chapter. Decriminalize Nature has influenced similar measures in Detroit, Oakland, Seattle, Denver and Washington, DC, as well as other counties and cities in the country. The city’s initiative references SB 519, a California bill forwarded by Sen. Scott Wiener. This bill called for the decriminalization of a range of psychedelics,…

FridaySep 16, 2022 2:29 pm

San Francisco Passes Resolution to Decriminalize Psilocybin Mushrooms

Last week, San Francisco became the latest and largest city in America to decriminalize psychedelics, including psilocybin mushrooms and ayahuasca. This move to decriminalize comes as a Senate bill from the state of California, which called for the decriminalization of psilocybin mushrooms, DMT, MDMA, LSD and ibogaine, was put on ice until 2023. During a meeting held last week, San Francisco’s Board of Supervisors unanimously approved a resolution that would make arresting individuals for the use, cultivation and distribution of federally banned psychedelics the lowest enforcement priority for law enforcement in the county. The resolution was introduced and sponsored by…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000